Trial of Indole-3-Carbinol and Silibinin
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 21
- Registration Number
- NCT03687073
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
A Study of FMT in Patients With AML Allo HSCT in Recipients
Phase 2
Completed
- Conditions
- Allogeneic Hematopoietic Cell TransplantationAcute Myeloid Leukemia
- Interventions
- Biological: Fecal Microbiota Transplant (FMT)Other: Placebo
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 100
- Registration Number
- NCT03678493
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Phase 2
Active, not recruiting
- Conditions
- Acute Lymphocytic LeukemiaRelapsed Large Cell LymphomaMantle Cell LymphomaAcute Myeloid LeukemiaMyelodysplasiaBurkitt LymphomaHodgkin LymphomaRelapsed T-Cell LymphomaBiphenotypic/Undifferentiated LeukemiaLymphoplasmacytic Lymphoma
- Interventions
- Drug: Total Body Irradiation (TBI)Drug: Granulocyte Colony-Stimulating Factor (G-CSF)Drug: MGTA 456 Infusion
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 22
- Registration Number
- NCT03674411
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Phase 2
Active, not recruiting
- Conditions
- Large B-cell LymphomaAcute Lymphoblastic Leukemia
- Interventions
- Drug: Abecma, Intravenous Suspension
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 144
- Registration Number
- NCT03642626
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
COMET2 Project 1 Filter Ventilation Study
Phase 3
Completed
- Conditions
- SmokingTobacco Use
- Interventions
- Other: Unventilated cigarettes onlyOther: Ventilated cigarettes only
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 118
- Registration Number
- NCT03637972
- Locations
- 🇺🇸
University of Minnesota Tobacco Research Program, Minneapolis, Minnesota, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Improving Self-Efficacy, Resolving Inflammaging Allo HSCT Survivors in Personal Training
Completed
- Conditions
- Allogeneic HCT Survivors
- Interventions
- Other: 10 Weeks of Strength Trailing
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 25
- Registration Number
- NCT03609203
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Phase 2
Recruiting
- Conditions
- Fanconi AnemiaSevere Aplastic AnemiaMyelodysplastic SyndromesT Cell Receptor Alpha/Beta DepletionTelomere Biology DisorderBone Marrow FailureDyskeratosis Congenita
- Interventions
- Drug: Total Body Irradiation (TBI) (Plan 1)Device: Donor mobilized PBSC infusion
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 48
- Registration Number
- NCT03579875
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
Terminated
- Conditions
- Immune and Microbial ReconstitutionRecurrent MalignancyCytokine Release SyndromeCell Therapy/Immunotherapy PatientsSystemic Viral InfectionChronic Graft-versus-host-diseaseAllogenic Related DonorsAcute-graft-versus-host Disease
- Interventions
- Diagnostic Test: Blood SampleDiagnostic Test: Apheresis ProductDiagnostic Test: Skin biopsyDiagnostic Test: Final cellular productDiagnostic Test: Stool SampleDiagnostic Test: Bronchoalveolar Lavage (BAL) fluidDiagnostic Test: Skin, mouth, and/or ocular swabDiagnostic Test: Urine SampleDiagnostic Test: Gastrointestinal biopsy x 2-4
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 210
- Registration Number
- NCT03557749
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Ethnic/Racial Differences in Metabolism and DNA Adduct Formation
Withdrawn
- Conditions
- Lung Cancer
- Interventions
- Diagnostic Test: Urine Sample
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT03421678
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
Phase 2
Completed
- Conditions
- Acute Myeloid LeukemiaHigher Risk Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 12
- Registration Number
- NCT03417154
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath